Publications
- Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Multiple sclerosis patient suitable for the treatment with ofatumumab2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab - a highly effective therapy for relapsing-remitting multiple sclerosis available in the first line2022 | Faculty of Medicine in Hradec Králové
- Long‑term effect of siponimod on MRI outcomes in patients with secondary‑progressive multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Biological treatment of multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Siponimod in the treatment of secondary - progressive multiple sclerosis - case report2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab and siponimod in the treatment of multiple sclerosis - case reports2022 | Faculty of Medicine in Hradec Králové
- Treatment persistence to ocrelizumab and local experience2021 | Faculty of Medicine in Hradec Králové
- Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis2021 | Faculty of Medicine in Hradec Králové
Loading network view...